

1 **Long-term humoral response following simultaneous Delta and Omicron BA.1**  
2 **co-infection**

3 Carla Saade, Msc<sup>1</sup>, Bruno Pozzetto, MD, PhD<sup>1,2</sup>, Melyssa Yaugel Novoa, Msc<sup>1</sup>, Bruno Lina,  
4 PhD<sup>1,3</sup>, Stéphane Paul, PhD<sup>1,2</sup>, Antonin Bal, PhD<sup>1,3</sup>, Sophie Trouillet-Assant\*, PhD<sup>1,4</sup> on behalf  
5 of Lyon COVID study group<sup>#</sup>

6 <sup>1</sup>CIRI - Centre International de Recherche en Infectiologie, Université Claude Bernard Lyon 1,  
7 Inserm, U1111, CNRS, UMR5308, ENS Lyon, Université Jean Monnet de Saint-Etienne, Lyon,  
8 France.

9 <sup>2</sup>Immunology laboratory, CIC1408, CHU Saint-Etienne, Saint-Etienne, France

10 <sup>3</sup>Laboratoire de Virologie, Institut des Agents Infectieux, Laboratoire associé au Centre  
11 National de Référence des virus des infections respiratoires, Hospices Civils de Lyon, F-  
12 69004, Lyon, France.

13 <sup>4</sup>Joint Research Unit Civils Hospices of Lyon-bioMérieux, Hospices Civils de Lyon, Hôpital  
14 Lyon Sud, Pierre-Bénite, 69310, France

15 <sup>#</sup>Study Group team members are listed in the Acknowledgments

16 \*Corresponding Author:

17 Sophie Trouillet-Assant, e-mail: [sophie.assant@chu-lyon.fr](mailto:sophie.assant@chu-lyon.fr); address: Hospices Civils de Lyon,  
18 France, International Center of Research in Infectiology, Team VirPath, Univ Lyon, Inserm,  
19 U1111, Université Claude Bernard Lyon 1, Université de Saint-Etienne, CNRS, UMR5308, ENS  
20 de Lyon, 69007 Lyon, France. Fax +33-4-72-67- 87-87

21 **Abstract:**

22 To provide insight into the long-term immune response following bivalent vaccines, we  
23 sampled vaccinated patients simultaneously co-infected with Delta and BA.1. We reported  
24 that simultaneous exposure to the Delta and BA.1 S protein does not confer an additional  
25 immune advantage compared to exposure to the Omicron BA.1 S protein alone.

26 **Keywords:** SARS-CoV-2 co-infection, long-term immune response, bivalent vaccines

27 Bivalent vaccines containing two different sequences of the Spike (S) protein have been  
28 recently approved. First studies evaluating the short-term immune response after the  
29 administration of bivalent vaccines have reported contradictory results<sup>1-3</sup>. Moreover, the  
30 long-term immunity outcomes of this bivalent vaccine need further investigation, especially  
31 given the waning of the humoral response. Others and we have reported cases of  
32 simultaneous co-infection by the Delta and BA.1 variants, both have caused major COVID-19  
33 epidemic waves worldwide<sup>4,5</sup>. The present report describes the long-term humoral response  
34 of patients co-infected with the variants Delta and BA.1 and aims at providing insights into  
35 that induced by bivalent vaccines.

36 We included two groups of fully vaccinated individuals with a breakthrough infection (BA.1  
37 in the first group [n=9] and Delta and BA.1 co-infection in the second group [n=9]) as well as  
38 a third group of COVID-19-naïve individuals who received three doses of the BNT162b2  
39 vaccine (n=9) (Table S1). Blood sampling was performed 6 months after breakthrough  
40 infection for infected individuals or after the third vaccine injection for COVID-19-naïve  
41 individuals (Table S1). Statistical analyses were performed using the GraphPad Prism®  
42 software (version 8; GraphPad software, La Jolla, CA, USA). Participants were included from two  
43 clinical studies registered on ClinicalTrial.gov (NCT05060939, NCT04341142). Written informed  
44 consent was obtained from all participants and approval was obtained from the regional review  
45 board in April 2020 (*Comité de Protection des Personnes Sud Méditerranée I*, Marseille, France;  
46 ID-RCB 2020-A00932-37; ID-RCB 2021-A01877-34).

47 There was no significant difference in anti-RBD IgG and anti-S1 IgA levels among individuals  
48 with a breakthrough infection caused by Delta and BA.1 or by BA.1 only; however these  
49 levels were 4.13 and 10.83 fold lower, respectively, among COVID-19-naïve individuals (Fig.  
50 1A and 1B).

51 Neutralizing antibody titers were significantly lower among COVID-19-naïve individuals for  
52 all viral variants compared to BA.1-infected and Delta-BA.1-co-infected individuals.  
53 Compared to COVID-19-naïve individuals, the median neutralizing antibody titer of BA.1-  
54 infected individuals was 8-fold higher for the 19A isolate and 12-fold higher for the BA.5  
55 isolate, and it was 8-fold higher for the 19A isolate and 16-fold higher for the BA.5 isolate for  
56 Delta-BA.1 co-infected individuals. Interestingly, no significant difference was observed  
57 between the two groups of individuals with a breakthrough infection (Fig. 1C).

58 Results reported herein showed an enhanced humoral response after breakthrough  
59 infections caused by one or two variants. These results confirmed the advantage conferred  
60 by so-called hybrid immunity, that has already been shown to induce a more potent long-  
61 term immune response against SARS-CoV-2 in comparison to that induced by vaccination  
62 only<sup>6</sup>.

63 In addition, the absence of significant difference in anti-S total antibodies and neutralization  
64 capacity between individuals with a single or a dual breakthrough infection would suggest  
65 that a simultaneous exposure to the Delta and Omicron BA.1 variants does not confer an  
66 additional immune advantage in terms of humoral immunity. Our results suggest that a  
67 combined exposure to two different S proteins, such as in the case of bivalent vaccines, does  
68 not confer a long-term immune advantage in comparison to a sequential exposure to  
69 different S proteins. Studies conducted by Wang et al. and Collier et al. investigated the  
70 immune response following a bivalent vaccination in comparison to a monovalent  
71 vaccination<sup>2,3</sup>. These studies showed no significant difference in neutralization capacity  
72 against Omicron subvariants between bivalent and monovalent vaccination. These results  
73 indicated the possibility of an immune imprinting in the context of anti-SARS-CoV-2

74 response, also known as original antigenic sin. This phenomenon is in reference to a limited  
75 immune response against a new antigen variant after an exposure to the initial antigen.

76 As our series was limited to cases of spontaneous infections with two different variants,  
77 studies comparing the long-term immune response induced after a challenge using a  
78 monovalent or a bivalent vaccine in COVID-19-naïve individuals are needed to evaluate the  
79 true benefit of the second strategy.

80 **Acknowledgment.** We thank all the staff members of the SARS-CoV-2 testing centre of the  
81 Hospices Civils de Lyon who contributed to the sample collection. We thank Cecile Barnel,  
82 the Clinical Research Associates, for her excellent work. We thank all the technicians from  
83 the virology laboratory whose work made it possible to obtain all these data. We thank all  
84 the members of the clinical research and innovation department for their reactivity (DRCI,  
85 Hospices Civils de Lyon). We thank H el ene Boyer (DRCI, Hospices Civils de Lyon) for her help  
86 in manuscript preparation. We thank all members of the Lyon Covid-ser study group: Jean-  
87 Baptiste Fassier, Nicolas Guibert, Dulce Alfaiate, Am elie Massardier-Pilonchery, Vanessa  
88 Escuret, H el ene Lozano, Laurence Josset, Bouchra Mokdad, Fanny Joubert and Camille  
89 Mena. Lastly, we thank all the participants for their involvement in this clinical study.

90 **Financial support.** This study has benefited from funding from the *Agence Nationale de*  
91 *Recherches sur le Sida et les H epatitis Virales* (ANRS-0154).

92 **Potential conflicts of interest.** All authors report no potential conflict of interest.

93 **References**

- 94 1. Chalkias, S. *et al.* A Bivalent Omicron-Containing Booster Vaccine against Covid-19. *New*  
95 *England Journal of Medicine* **0**, null (2022).
- 96 2. Wang, Q. *et al.* Antibody responses to Omicron BA.4/BA.5 bivalent mRNA vaccine booster  
97 shot. 2022.10.22.513349 Preprint at <https://doi.org/10.1101/2022.10.22.513349> (2022).
- 98 3. Collier, A. Y. *et al.* Immunogenicity of the BA.5 Bivalent mRNA Vaccine Boosters.  
99 2022.10.24.513619 Preprint at <https://doi.org/10.1101/2022.10.24.513619> (2022).
- 100 4. Bal, A. *et al.* Detection and prevalence of SARS-CoV-2 co-infections during the Omicron  
101 variant circulation, France, December 2021 - February 2022. 2022.03.24.22272871  
102 Preprint at <https://doi.org/10.1101/2022.03.24.22272871> (2022).
- 103 5. Rockett, R. J. *et al.* Co-infection with SARS-CoV-2 Omicron and Delta variants revealed by  
104 genomic surveillance. *Nat Commun* **13**, 2745 (2022).
- 105 6. Andreano, E. *et al.* Hybrid immunity improves B cells and antibodies against SARS-CoV-2  
106 variants. *Nature* (2021) doi:10.1038/s41586-021-04117-7.
- 107 7. Pozzetto, B. *et al.* Immunogenicity and efficacy of heterologous ChadOx1/BNT162b2  
108 vaccination. *Nature* (2021) doi:10.1038/s41586-021-04120-y.
- 109

110 **Figure 1. Humoral immune response 6 months after immunization in individuals**  
111 **vaccinated and then co-infected with Delta and BA.1, or vaccinated and then infected with**  
112 **BA.1, or in COVID-19-naïve fully-vaccinated individuals**

113 Blood samples were obtained 6 months after infection or 6 months after the booster  
114 injection from 9 individuals in each group of patients.

115 Anti-RBD IgG levels were measured using the bioMérieux Vidas SARS-CoV-2 IgG diagnosis kit  
116 according to manufacturer's recommendations and expressed in binding antibody unit (BAU)  
117 /mL. The dotted line represents the threshold of positivity ( $\geq 20.33$  BAU/mL) (**Panel A**).

118 Anti-S1 IgA levels were measured using an ELISA test as previously described <sup>7</sup> and expressed  
119 in  $\mu\text{g/mL}$ . The dotted line represents the positivity threshold ( $\geq 0.0018$   $\mu\text{g/mL}$ ) (**Panel B**).

120 Neutralizing antibody titers against live SARS-CoV-2 isolates using a 50% plaque reduction  
121 neutralization test (PRNT<sub>50</sub>), as previously described <sup>7</sup>. The isolates used for these  
122 experiments were 19A, Delta, Omicron BA.1, BA.4, and BA.5; their GISAID accession numbers  
123 are EPI\_ISL\_1707038, EPI\_ISL\_1904989, EPI\_ISL\_7608613, EPI\_ISL\_12396843, and  
124 EPI\_ISL\_12852091, respectively. The dotted line represents the positivity threshold (titer  $\geq$   
125 20) (**Panel C**).

126 Data are represented as box and whiskers plot; in each plot, the dots indicate individual  
127 samples, the upper and lower limits of the box plot represent the interquartile [IQR] range  
128 and the middle line represents the median. A Kruskal-Wallis test followed by Dunn's multiple  
129 comparison tests were performed to assess differences between the three groups.



